Regeneron Pharma (REGN) PT Raised to $850 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel deepen AI capex concerns
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $913.41 +11.56%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 44 | New: 9
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 44 | New: 9
Join SI Premium – FREE
JPMorgan analyst Chris Schott raised the price target on Regeneron Pharma (NASDAQ: REGN) to $850.00 (from $750.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Regeneron (REGN) Tops Q3 EPS by $4.01, Beats on Revenue
- Eli Lilly (LLY) PT Raised to $1,600 at RBC Capital After an 'Impressive Quarter'
- Stryker (SYK) PT Lowered to $309 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
